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Introduction: The objective of this paper is to systematically review the existing evidence of 
the effectiveness and safety profile of a long-acting inhaled muscarinic antagonist as add-on 
therapy in patients with asthma that is uncontrolled despite inhaled corticosteroid (ICS) use.
Methods: With the assistance of two experienced research librarians, we searched Ovid 
MEDLINE/PubMed (1946 to September 12, 2013), the Cochrane Library review, and the TRIP 
database. The key search terms were “tiotropium and asthma.” The search was limited to human 
data published in English. Included in the systematic review were all randomized controlled 
trials that evaluated the efficacy of tiotropium in patients with asthma. The clinical trials had 
to be at least 4 weeks in duration and to provide adequate information on clinically appropriate 
end points in asthma care (eg, change in lung function, exacerbation rates, and/or ICS dosing). 
Data on patient characteristics, study design, outcome measures, concomitant asthma medica-
tion, and adverse events were extracted from the full text of each included individual study. 
Marked heterogeneity of study design precluded statistical pooling of results for a meta-analysis. 
Consequently, only descriptive summaries of outcomes are provided.
Results: Our database search retrieved 149 citations. We found five randomized controlled trials in 
humans that met our criteria for inclusion in the systematic review. We also found two open-label 
uncontrolled trials that were considered in the discussion. Each of the five included studies met 
the Consolidated Standards of Reporting Trials criteria for a well-designed randomized trial.
Discussion: The five clinical studies included in this systematic review focused on evaluating the 
efficacy of tiotropium as add-on therapy to ICS or ICS in combination with a long-acting inhaled 
β
2
-agonist (LABA) in patients with uncontrolled moderate to severe persistent asthma. Tiotro-
pium maintained lung function when ICSs were tapered and when an LABA was discontinued. 
Tiotropium improved lung function when added to ICS alone or ICS–LABA combination therapy. 
In the only trial to have compared the addition of tiotropium with doubling the dose of ICS, 
tiotropium provided significantly superior results. In trials in which the addition of tiotropium 
was compared with salmeterol, the beneficial effects of these two bronchodilators were similar. 
No safety concerns were found with use of tiotropium as add-on therapy.
Conclusion: Tiotropium may have a beneficial role in moderate to severe persistent asthma despite 
use of an ICS or ICS and LABA. Use of tiotropium as add-on therapy poses no safety concerns.
Keywords: tiotropium, asthma, lung, inflammation, inhaled corticosteroid, LABA, LAMA 
Introduction
Asthma is a chronic inflammatory airway disease.1 Airway inflammation in asthma 
is characterized by bronchial wall infiltration by eosinophils, activated mast cells, 
and T lymphocytes. Cytokines from T helper 2 cells and leukotrienes play key roles 
in mediating airway inflammation. Also seen are goblet cell hyperplasia, mucus 
gland hypertrophy, and airway mucus accumulation. Increased airway smooth 
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muscle mass and reversible bronchoconstriction are other 
important features of asthma. Airway inflammation, mucus 
accumulation, and bronchospasm account for the symptoms 
of shortness of breath, wheezing, cough, and chest tight-
ness in asthma.1 Understanding asthma pathophysiology is 
an important issue for health care practitioners in the US 
because asthma prevalence increased from 7.3% in 2001 to 
8.4% in 2010. In 2010, an estimated 25.7 million Americans 
had asthma – 18.7 million adults aged 18 years and over and 
7.0 million children aged 0–17 years.2
The ultimate goal of asthma management is to minimize 
symptoms, prevent acute exacerbations, and avoid adverse 
medication effects. The pathophysiologic features of 
asthma explain why current US and international guide-
lines recommend the use of an inhaled corticosteroid 
(ICS) and a short-acting inhaled β
2
-agonist (SABA) for 
treatment of persistent asthma.3,4 ICSs can control airway 
inflammation,5,6 and SABAs can manage acute symptoms 
related to bronchospasm. To reduce the risk of drug-related 
side effects, current asthma management guidelines recom-
mend a stepwise treatment approach to achieving optimal 
asthma control, with more aggressive ICS dosing reserved 
for patients with more severe disease.3,4 However, prospective 
studies have confirmed that a significant proportion of asthma 
patients do not achieve asthma control, even with maximal 
approved doses of ICS.7 In patients who do not respond to 
ICS treatment alone, asthma guidelines recommend addi-
tion of another long-term controller, such as a long-acting 
inhaled β
2
-agonist (LABA), a leukotriene-modifying agent 
(LMA), theophylline, and/or an anti-immunoglobulin E 
monoclonal antibody. Despite the addition of agents like 
LABAs and LMAs to ICSs, many asthma patients still 
remain both symptomatic and obstructed.8 There is clearly 
a need for alternative medications with different modes of 
action in asthma management. One intriguing option as an 
add-on therapy for asthma patients not responding to ICSs 
is an anticholinergic.
Tiotropium bromide is a long-acting inhaled muscar-
inic antagonist (LAMA). It has high potency as a selective 
antagonist at the muscarinic acetylcholine (Ach) receptors. 
Tiotropium rapidly dissociates from M2 Ach receptors but 
slowly dissociates from M3 Ach receptors.9 Consequently, 
tiotropium provides 24-hour bronchodilation as mainte-
nance therapy in moderate to severe chronic obstructive 
pulmonary disease (COPD).10,11 Tiotropium has also been 
shown to reduce goblet cell metaplasia and airway smooth 
muscle mass in allergen-challenged mice and guinea pigs.12,13 
Early evidence of clinical benefit with LAMA therapy 
in asthma was identified in COPD patients with airway 
hyper-responsiveness and concomitant asthma.14–16
The objective of this paper is to systematically review the 
existing evidence of the use of tiotropium in patients with 
uncontrolled asthma and to provide recommendations for its 
potential role in the treatment of asthma. We sought to answer 
the question what is the existing evidence of the effectiveness 
and safety profile of an LAMA as add-on therapy in patients 
with asthma that is uncontrolled despite ICS use?
Materials and methods
Search strategy and study selection
We adhered to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) criteria when per-
forming this study.17 With the assistance of two experienced 
research librarians, we searched Ovid MEDLINE/PubMed 
(1946 to September 12, 2013), the Cochrane Library 
review, and the TRIP database. The key search terms were 
“tiotropium and asthma.” The search was limited to human 
data published in English.
Abstracts of articles identified in the search were reviewed 
independently by two of the authors. Articles meeting pre-
identified inclusion and exclusion criteria were selected for 
evaluation in this systematic review. Disagreements about 
inclusion of individual articles were resolved by consensus 
or review by a third author. Included in the systematic review 
were all randomized controlled trials that evaluated the 
efficacy of tiotropium in patients with asthma. The clinical 
trials had to be at least 4 weeks in duration and to provide 
adequate information on clinically appropriate end points in 
asthma care (eg, change in lung function, exacerbation rates, 
and/or ICS dosing). Excluded were unpublished and ongoing 
research, animal studies, reviews, case reports, case series, 
editorials, and studies in COPD patients (with or without 
asthma). The references of published articles identified in 
the search were examined for additional studies appropriate 
for inclusion in the review.
Data extraction and quality assessment
Data on patient characteristics, study design, outcome mea-
sures, concomitant asthma medication, and adverse events 
were extracted from the full text of each included individual 
study. The methodologic quality of the trials was evaluated 
using criteria reported in the Consolidated Standards of 
Reporting Trials (CONSORT) Statement.18 Marked het-
erogeneity of study design precluded statistical pooling of 
results for a meta-analysis. Consequently, only descriptive 
summaries of outcomes are provided.
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Results
Our database search retrieved 149 citations of which 93 were 
excluded because they did not meet the inclusion criterion of 
being specific to the effect of tiotropium in asthma (Figure 1). 
An additional 37 citations were excluded because they did 
not describe results of clinical trials in humans. Twelve other 
citations were not included. Two were single-patient case 
reports, one was in Japanese, six had duplicate information, 
and three studies did not make a distinction between asthma 
and COPD.
We found five randomized controlled trials in humans that 
met our criteria for inclusion in the systematic review.19–23 
One open-label study without a control was identified in the 
database search.24 This study was not included in the system-
atic review but was considered in the discussion. Following 
review of the references of the selected papers, an additional 
open-label trial without a control group was identified.25 
This study was not included in the systematic review but 
was considered in the discussion. Summary descriptions of 
the five publications that met inclusion criteria are provided 
in Tables 1 and 2. Detailed descriptions of the five selected 
studies are provided as follows.
Fardon et al19 evaluated the ICS sparing ability of 
 tiotropium in patients with severe persistent asthma. 
Citations excluded (n=93) 
Not specific to the analysis of tiotropium in asthma (n=93)   
Citations specific to tiotropium in asthma (n=56)   
Citations excluded (n=37)
Review articles (n=13), letters, comments, or expert opinion
(n=18) and animal studies with no clinical end points (n=6) 
Citations describing results of tiotropium clinical experience (n=19) 
Citations excluded (n=12)
Case reports (n=2), Japanese language (n=1),
duplicates (n=6), and trials that included COPD
patients (n=3)    
Citations describing results of controlled clinical trials with tiotropium in asthma (n=7)  
Citations identified from Ovid and PubMed (n=149)
Citations excluded (n=2)
Open-label trials (n=2)  
Total publications reviewed (n=5)  
Figure 1 Selection process of citations.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Befekadu et al
 Inclusion criteria for this clinical trial required that study 
patients be adults with a clinically established diagnosis 
of asthma and with .15% reversibility after an SABA 
or a short-acting inhaled muscarinic antagonist (SAMA). 
 Inclusion criteria also required a forced expiratory volume 
in 1 second (FEV
1
) of #65%. Patients were excluded if they 
had had a recent exacerbation or had smoked at any time 
during their life. The study was a double-blind, random-
ized, placebo-controlled, crossover study. Patients were 
changed from their usual asthma medications to 1,000 μg 
of fluticasone daily for a 4-week run-in period. Their dose 
of fluticasone was then halved to 500 μg/day and an LABA 
was added (125/25 μg per puff and two puffs twice daily). At 
that point, patients entered a crossover phase in which they 
were randomized, first, to the addition of either tiotropium 
bromide (18 μg administered once daily from a metered dose 
inhaler) or a matched placebo before, secondly, receiving 
the other treatment. The crossover phases lasted 4 weeks 
and there was no washout period between study phases. 
A specific primary outcome measure was not identified in 
this study. Twenty-six lifelong nonsmoking severe asthmat-
ics with a mean FEV
1
 of 1.49 L (51% predicted) entered 
the run-in phase, but only 18 patients completed the study. 
Four weeks after patients were switched from fluticasone 
1,000 μg/day to the lower dose of ICS with an LABA for 
the run-in period, there were significant increases in morning 
(AM) and evening (PM) peak expiratory flow (PEF). Four 
weeks after switching to the combination of an ICS–LABA 
with tiotropium there were significant improvements in 
FEV
1
 (0.17 L; 95% confidence interval [CI]: 0.01–0.32; 
P,0.05) and forced vital capacity (FVC) (0.24 L, 95% 
CI: 0.05–0.43; P,0.05). The ICS– LABA–tiotropium com-
bination also resulted in reduced exhaled nitric oxide levels 
by 2.86 ppb (95% CI: 0.12–5.6; P,0.05). The increases in 
lung  function with the triple combination of ICS–LABA–
tiotropium were not significantly different from the changes 
found with the ICS–LABA combination, though. Although 
there were small improvements in subjective symptoms 
of quality of life, measured by the Mini Asthma Quality 
of Life Questionnaire (Mini AQLQ) after both crossover 
phases, the changes were not significant. The small sample 
size and the fact that eight of the participants dropped out 
due to an asthma exacerbation were mentioned as possible 
reasons for the failure of the study to detect improvement 
in quality of life. The authors also evaluated acute changes 
in lung function after single doses of an SABA with an 
SAMA. There was a significant bronchodilator benefit after 
the inhalation of albuterol and ipratropium, but the response 
to short-acting inhaled bronchodilators did not predict the T
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response to tiotropium. Safety information was not provided 
in this study.
Peters et al20 compared the benefit of tiotropium as 
add-on therapy to an ICS with that obtained by either add-
ing an LABA or doubling the ICS dose in patients with 
uncontrolled persistent asthma. Patients were included if 
they were nonsmokers (less than 10 pack-years per life-
time), were aged 18 years or older, had an FEV
1
 .40% of 
the predicted value, and had a diagnosis of asthma con-
firmed by bronchodilator reversibility or bronchial hyper-
responsiveness. The study was a three-way, double-blind, 
triple-dummy, crossover trial. Patients entered a 4-week 
run-in period during which they were treated with 160 μg 
of beclomethasone daily. They were entered into the trial 
if they had either an FEV
1
 #70% or daytime symptoms 
for 6 or more days per week or night-time symptoms 2 or 
more nights per week during the final 2 weeks of the run-in 
period. The three crossover periods involved adding tiotro-
pium (18 μg every AM from a dry powder inhaler), adding 
salmeterol (50 μg twice daily by dry powder inhaler), or 
doubling the ICS to 320 μg daily. Each treatment period 
lasted 14 weeks with a 2-week washout phase between 
treatment periods. The identified primary outcome measure 
in this study was the AM PEF, and the primary hypothesis 
was that the addition of tiotropium to ICS would provide 
greater benefit than doubling the dose of ICS. Two hun-
dred and ten severe asthma patients with a mean FEV
1
 of 
2.31 L (71.5% predicted) met the entry criteria and were 
randomized. Thirty-six participants dropped out during 
the treatment phase due to withdrawal of consent, loss to 
follow-up, drug-related adverse events, or miscellaneous 
reasons. The use of tiotropium resulted in a superior 
primary outcome compared with doubling the dose of an 
ICS. There was a greater improvement in the primary out-
come measure AM PEF with tiotropium compared with a 
double dose of ICS, with a mean difference of 25.8 L/min 
(P,0.001). Tiotropium also showed superiority in most 
secondary outcomes. PM PEF was larger, with a difference 
of 35.5 L/min (P,0.001); the proportion of asthma control 
days was greater, with a difference of 0.079 (P=0.01); the 
FEV
1
 before bronchodilation was larger, with a difference 
of 0.10 L (P=0.004); and daily asthma symptom scores 
were lower, with a difference of -0.11 points (P,0.001). 
In the secondary outcome analysis, addition of tiotropium 
to an ICS was found to be noninferior to salmeterol, as 
measured by the AM PEF. Although the prebronchodilator 
and postbronchodilator FEV
1
 responses favored tiotropium, 
tiotropium was noninferior to salmeterol in other results, 
including PM PEF, asthma daily symptom scores, and 
sputum eosinophils. Interestingly, a small FEV
1
 decrease 
in patients receiving albuterol in addition to the standing 
dose of salmeterol suggested a tachyphylaxis effect for 
β-agonists that was not found in the tiotropium group. Not 
increasing the dose of ICS by more than a factor of two was 
proposed as a potential weakness of the trial, together with 
the short study duration (14 weeks) and the small sample 
size. Although long-term safety issues were not assessed in 
this trial, numerically more asthma exacerbations occurred 
during the double-dose ICS treatment period than during the 
tiotropium treatment period (n=16 versus [vs] n=9), with the 
fewest occurring with salmeterol treatment (n=5).
Kerstjens et al21 sought to compare the efficacy and 
safety of different doses of tiotropium in the Respimat® 
inhaler (Boehringer Ingelheim Pharma GmbH and Co, KG, 
Ingelheim, Germany) against placebo as add-on therapy in 
patients with uncontrolled severe persistent asthma. Patients 
included in this trial were aged 18 years and older and had at 
least a 5-year history of asthma. They were required to have 
a postbronchodilator FEV
1
 #80% and to have an Asthma 
 Control Questionnaire (ACQ) score of $1.5 despite treatment 
with high-dose ICS and an LABA. Interestingly, patients were 
allowed to remain on a stable dose of theophylline, LMA, 
and oral corticosteroid throughout the study. Patients were 
excluded if they had a smoking history of $10 pack-years or 
a diagnosis of COPD. The authors conducted a randomized, 
double-blind, crossover study with three 8-week treatment 
periods. After a 2-week run-in period, eligible patients were 
randomized to receive each of three treatments in a random 
sequence for 8 weeks in a crossover design (5 μg or 10 μg of 
tiotropium or matching placebo administered as two actua-
tions once daily in the AM from the Respimat inhaler). There 
was no washout phase between treatment periods. Throughout 
the 24-week treatment period, participants recorded PEF and 
FEV
1
 values twice daily at home using the Asthma Monitor 
AM2+ and responded to daily questions in the electronic 
diary component of this device. The primary end point was 
peak FEV
1
 (obtained within 3 hours of dosing) at the end 
of each treatment period. Of the 107 randomized patients, 
100 completed all treatment periods. Peak FEV
1
 was signifi-
cantly higher with 5 μg of tiotropium (difference 139 mL; 
95% CI: 96–181 mL) and 10 μg (difference 170 mL; 95% 
CI: 128–213 mL) than with placebo (both P,0.0001). Trough 
FEV
1
 at the end of the dosing interval was also higher with both 
doses of tiotropium than with placebo (difference with 5 μg of 
86 mL [95% CI: 41–132]; difference with 10 μg of 113 mL 
[95% CI: 67–159 mL], both P,0.0004). Although there 
were numerically greater FEV
1
 responses with the 10 μg dose 
of tiotropium than with the 5 μg dose compared with placebo 
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for both peak and trough FEV
1
, the differences in outcome 
measures between the two active doses were not significant. 
Across groups, no significant difference was noted in asthma-
related health status, rescue medication use, or symptoms 
measured in the electronic diary. There was a trend for more 
adverse events to be reported with the 10 μg tiotropium treat-
ment group than with the placebo group. Patients receiving 
the highest dose of tiotropium specifically reported more 
complaints about dry mouth than the placebo group (6.8% 
vs 1.0%). Serious adverse events and asthma exacerbations 
were few and balanced among the treatment groups.
Bateman et al22 compared the efficacy and safety of 
tiotropium as add-on therapy to patients with moderate 
persistent asthma not adequately controlled by ICS therapy 
alone against salmeterol and placebo. As a novel twist of this 
study, the authors focused their study on a specific group of 
asthma patients with the B16-Arg/Arg genotype. Patients 
with a history of asthma with the B16-Arg/Arg genotype and 
receiving maintenance therapy with ICS of 400–1,000 μg/day 
of budesonide or equivalent were eligible for enrollment. The 
main inclusion criteria were reversible airway obstruction 
(improvement in FEV
1
 of at least 12% and 200 mL after 
sequential inhalation of 80 μg of ipratropium bromide and 
400 μg of salbutamol) and prebronchodilator FEV
1
 of 90% 
of predicted value or less for patients previously receiving a 
daily dose of at least 100 μg of salmeterol or 18 μg of formot-
erol and an ICS of 80% of predicted value or less for patients 
previously receiving ICSs only. The main exclusion criteria 
were smoking history (.10 pack-years), COPD, serious con-
comitant illnesses, and concomitant respiratory medications. 
They conducted a double-blind, double-dummy, placebo-
controlled, parallel-group trial. There was a 4-week run-in 
period during which patients received 50 μg of twice-daily 
salmeterol administered through a metered dose inhaler along 
with their ICS. After the run-in period, patients were random-
ized to 16 weeks of treatment with tiotropium (two puffs of 
2.5 μg daily in the PM through the Respimat inhaler), sal-
meterol metered dose inhaler (two puffs of 25 μg twice daily 
plus tiotropium-matching placebo), or placebo (with both a 
tiotropium and salmeterol matching placebo). The primary 
end point was change in weekly AM (predose) PEF from 
the last week of run-in period to the last week of treatment. 
A total of 530 patients were eligible for the trial and 388 were 
randomized. At baseline almost all patients were receiving 
ICSs. The majority of patients in each treatment group were 
also receiving an LABA. The prebronchodilator FEV
1
 was 
between 68% and 70% for the three treatment groups. There 
was, on average, between a 24% and 28% increase in FEV
1
 
after ipratropium and albuterol. The AM PEF was maintained 
with tiotropium (-3.9±4.87 L/min change from run-in) 
and salmeterol (-3.2±4.64 L/min change from run-in), but 
the AM PEF decreased with placebo (-24.6±4.84 L/min 
from run-in). Both active treatments provided significantly 
superior effects on AM PEF compared with placebo. The 
tiotropium effect was noninferior to salmeterol. Weekly FEV
1
 
measures showed the same treatment effects as the AM PEF. 
Surprisingly, little evidence of treatment effect with tiotro-
pium and salmeterol was found in asthma symptoms, rescue 
medication use, and the Mini AQLQ. In general, adverse 
event reporting was comparable across treatment groups. 
There were numerically more asthma exacerbations with 
salmeterol treatment (n=4) than with either placebo (n=1) 
or tiotropium (n=0).
In two large replicate studies, Kerstjens et al23 compared 
the effect of adding 5 μg of tiotropium each AM to placebo on 
lung function and exacerbations in poorly controlled asthma 
patients already receiving ICS and LABA. Included patients 
were aged between 18 years and 75 years and had a 5-year 
or longer asthma history. Other inclusion criteria consisted 
of an ACQ score of 1.5 or higher, a postbronchodilator 
FEV
1
 #80% predicted, and a postbronchodilator FVC #70% 
predicted despite daily therapy with high-dose ICS and 
LABA. Included patients also had at least one asthma exac-
erbation in the preceding year that required treatment with 
systemic corticosteroids. Main exclusion criteria consisted 
of a pre-existent diagnosis of COPD, serious coexisting ill-
ness, and concurrent use of anticholinergic bronchodilators. 
Patients with a $10 pack-years smoking history and who 
had smoked within the past year were also excluded. The 
study was a randomized, double-blind, placebo-controlled, 
parallel-group design. After a 4-week screening period, 
patients were randomized to treatment with either tiotropium 
(5 μg daily) or placebo, both administered by the Respimat 
Soft Mist Inhaler in the AM for 48 weeks, which made it 
the longest trial carried out on this subject. The primary 
outcomes were the peak FEV
1
 (measured within 3 hours of 
treatment) and trough FEV
1
 at week 24 expressed as change 
from baseline. In the two studies, 912 eligible patients were 
randomized. At 24 weeks, the mean change in the peak FEV
1
 
from baseline was greater with tiotropium than with placebo 
in the two trials: a difference of 86±34 mL in trial 1 (P=0.01) 
and 154±32 mL in trial 2 (P,0.001). Similar significant 
differences in favor of tiotropium treatment were found 
with the trough FEV
1
. The effects of tiotropium continued 
throughout the entire 48 weeks of the study. In addition, the 
addition of tiotropium increased the time to the first severe 
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exacerbation (282 days vs 226 days) with an overall reduc-
tion of 21% in the risk of a severe exacerbation (hazard ratio 
0.79; P=0.03). Consistent differences between tiotropium and 
placebo treatment on the ACQ, the AQLQ symptom-free 
days, and rescue medication use were not found, however. 
Adverse event reporting was slightly lower with tiotropium 
than with placebo. No differences were found between the 
groups in cardiac adverse events and serious adverse events. 
Treatment with tiotropium was associated with a slightly 
higher complaint rate of dry mouth.
We performed an assessment of the methodologic quality 
of the five studies, and we assessed the consistency and adher-
ence of the five trials to the CONSORT. We concluded that 
each study met the CONSORT criteria for a well-designed 
randomized trial.18
Discussion
Tiotropium is an inhaled long-acting anticholinergic cur-
rently approved in the US for once-daily maintenance 
treatment of bronchospasm associated with COPD.26 It has 
been proven to be an effective bronchodilator and to reduce 
the frequency of COPD exacerbations.10,11 Despite the 
well-studied pharmacology of tiotropium, its role in asthma 
remains unproven. The drug is currently not approved for 
non-COPD obstructive airway disease. In this systematic 
review we found that adding tiotropium to pre-existing 
therapy with only an ICS or an ICS–LABA combination 
resulted in significant improvements in lung function. There 
was also evidence from one study suggesting a reduction in 
exacerbations in patients with uncontrolled severe asthma. 
These observations are supported by findings in open-label, 
uncontrolled studies. The findings are consistent with the 
known effect of a muscarinic antagonist and its mechanism 
of action in the context of asthma pathophysiology.
The five clinical studies included in this systematic 
review focused on evaluating the efficacy of tiotropium as 
add-on therapy to ICS or ICS in combination with an LABA 
in patients with uncontrolled moderate to severe persistent 
asthma. Tiotropium maintained lung function when ICSs 
were tapered and when an LABA was discontinued.19,22 
Tiotropium improved lung function when added to an ICS 
alone or an ICS–LABA combination therapy.20–23 In the 
only trial to have compared the addition of tiotropium with 
doubling the dose of ICS, tiotropium provided significantly 
superior results.20 In trials in which the addition of tiotropium 
was compared with salmeterol, the beneficial effects of these 
two bronchodilators was similar.20,22 Although the improve-
ments in lung function appeared to be clinically meaningful, 
these clinical trials failed to show that tiotropium provided 
consistent and clinically relevant improvements in respiratory 
symptoms, rescue medication use, or quality of life. Perhaps 
the failure to show symptomatic improvements was a func-
tion of study size. In the one report powered sufficiently to 
assess any change in the symptomatic burden of asthma, 
the addition of tiotropium resulted in an overall reduction of 
exacerbations and an increase in the time between them.23 
Overall, the consistent improvement in lung function with 
the addition of tiotropium should probably lead to US Food 
and Drug Administration approval of tiotropium as add-on 
therapy for patients with uncontrolled moderate to severe 
persistent asthma already on ICSs. Unfortunately, the avail-
able information does not enable health care providers to 
determine whether an individual patient might respond more 
to tiotropium or an LABA as add-on therapy.27
Although excluded from the systematic review, the two 
open-label trials we found on this topic support the findings 
of the other five studies. Iwamoto et al24 added tiotropium to 
17 patients with severe persistent asthma who were receiving 
high-dose ICSs. Many of these patients were also taking an 
LABA and/or oral corticosteroids. The study was an open-
label, uncontrolled design. They found that use of tiotropium 
for 4 weeks significantly improved FEV
1
 (P=0.001). Of note, 
the percentage of eosinophils in the induced sputum of the 
participants was inversely correlated with the change in FEV
1
, 
whereas the neutrophil proportion was directly correlated with 
an increase in FEV
1
. This suggested that the noneosinophilic 
sputum profile may separate responders vs nonresponders 
to tiotropium therapy. A similar interest in distinguishing 
responders from nonresponders was reflected in the study 
conducted by Park et al.25 They studied 138 patients with 
severe persistent asthma who had reduced lung function despite 
high-dose ICSs and LABA. Tiotropium, administered as 18 μg 
daily from a dry powder inhaler, was added to this regimen. 
Lung function tests were evaluated every 4 weeks for a mini-
mum of 12 weeks. Responders were defined as having a .15% 
(or .200 mL) improvement in FEV
1
, with a sustained effect 
lasting at least 8 successive weeks. Forty-six of the 138 patients 
(33.3%) responded to tiotropium treatment. Logistic regression 
analysis (controlled for age, sex, and smoking status) showed 
that Arg16Gly in ADRB2 (P=0.003, odds ratio 0.21, 95% 
CI: 0.07–0.59) in a minor allele-dominant model was signifi-
cantly associated with the response to tiotropium.
Improved lung function (increased FEV
1
 and PEF) in 
asthma with tiotropium can be explained by its mechanism of 
action in the context of asthma pathophysiology. The major 
bronchi (the site of bronchoconstriction in asthma) have the 
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densest population of cholinergic nerves in the respiratory 
tract. Bronchoconstriction is mainly mediated through cho-
linergic mechanisms in humans.27 Stimulation of cholinergic 
fibers leads to activation of M3 Ach receptors in the airway 
smooth muscle, which, in turn, causes bronchoconstriction 
and mucus secretion. Tiotropium is an effective M3 Ach 
receptor antagonist. Cholinergic stimulation may also have 
influences in addition to controlling airway smooth muscle 
contraction. Cholinergic pathways influence mucus secretion 
and possibly airway inflammation. It has been speculated 
that tiotropium might be able to affect airway remodeling 
in asthma through these mechanisms.28,29
Only four of the clinical trials reported complete informa-
tion on adverse events related to tiotropium use. In general, 
similar total and individual reporting of adverse events was 
described for tiotropium and salmeterol compared with 
placebo. The only exception was that patients receiving higher 
doses of tiotropium (eg, 10 μg) tended to report dry mouth 
more frequently.21 The cardiovascular safety profile of tiotro-
pium is of particular interest. In COPD patients,  Verhamme 
et al30 found that tiotropium administered 5 μg daily by the 
Respimat Soft Mist Inhaler was associated with about a 
30% increase in mortality compared with a comparable dose 
of tiotropium administered by a dry powder inhaler. The 
mortality association was strongest for cardiovascular and 
cerebrovascular death. However, it remains unclear whether 
this association is causal or due to residual confounding by 
COPD severity. A more recent study, also performed in COPD 
patients, found that tiotropium administered by the Respimat 
Soft Mist Inhaler at a dose of 5 μg or 2.5 μg had a safety profile 
similar to that of tiotropium given by dry powder inhaler at a 
dose of 18 μg.31 The 48-week studies reported by Kerstjens 
et al23 described no deaths and few cardiovascular safety 
events in asthma patients using tiotropium administered by 
the Respimat Soft Mist Inhaler.
There are strengths and limitations to this systematic 
review. Although the number of studies included was small, 
the studies were of high quality. They were randomized and 
controlled. All studies met the CONSORT criteria for report-
ing of randomized trials. There were limitations, though, in 
the five studies. One study was small, with only 18 completed 
patients.19 Two studies were short, only 4 and 8 weeks.19,21 
Consequently, information available regarding sustainability 
of benefit is somewhat limited.23 The trials were a mixture of 
crossover and parallel-group design, making integration of effi-
cacy results impractical. There may still be unresolved issues 
regarding the appropriate dosing of tiotropium in the treatment 
of asthma. Different inhalation devices (with different doses) 
were used to administer tiotropium, metered dose inhaler,19 
dry powder inhaler,20 and the Respimat Soft Mist Inhaler.21–23 
One study compared the effect of 5 μg of tiotropium from 
the Respimat vs 10 μg. The effects on lung function of the 
10 μg tiotropium dose tended to be greater, but there was also 
a higher reporting rate of dry mouth with the larger dose. It 
is unclear whether the 10 μg tiotropium dose might provide 
additional benefits with long-term use, such as a further reduc-
tion in exacerbation rates. Although two of the studies using 
tiotropium in the Respimat had patients self-administer their 
dose in the AM, one of the studies required PM dosing.21–23 It 
is difficult to determine from these studies whether there might 
be greater benefits of PM vs AM dosing.
There was limited information available from these stud-
ies regarding the anti-inflammatory benefits of tiotropium 
in uncontrolled asthma. Fardon et al19 found that addition 
of tiotropium was associated with a significant reduction 
in exhaled nitric oxide levels, but Peters et al32 found that 
immunoglobulin E levels, sputum eosinophil counts, and 
exhaled nitric oxide levels were not predictive of a clinical 
response to tiotropium. Similarly, reversibility testing to 
either an SABA or an SAMA was not helpful in identifying 
patients who would have a beneficial tiotropium response.19 
Because all studies required SABA reversibility as an 
inclusion criterion, it is unclear whether an uncontrolled 
asthma patient with moderate to severe persistent disease 
but without reversibility would have a beneficial response 
to tiotropium.
In summary, there may be a beneficial role for tiotropium 
in moderate to severe persistent asthma patients who are 
uncontrolled despite use of an ICS or an ICS and an LABA. 
However, it remains to be determined whether the spiro-
metric changes will ultimately reciprocate in long-term 
symptom improvement. The currently available literature 
lays a sound foundation for further studies to be designed 
with particular focus on the asthma population. An important 
issue will be to determine whether patterns of genotypes, 
physiology, or inflammatory markers can be identified that 
would identify patients with the maximal potential benefit 
from treatment with tiotropium in addition to currently 
approved therapy.
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